Hariharan Jayaram

This inventor holds 12 USPTO granted patents and 12 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignee: Editas Medicine, Inc.. Active years: 2018-2025.

USPTO Granted Patents = 12 (Patent Applications = 12)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 8)

EPO Patents = 3 (Patent Applications = 15)

Average Co-Inventor Count = 3.1

ph-index = 3

Forward Citations = 20(Granted Patents)

Location History:

Cambridge, MA (US) (2018 - 2024)
San Mateo, CA (US) (2022 - 2024)

Company Filing History:

12 out of 53

Editas Medicine, Inc.

patents

Years Active: 2018-2025

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12325854 - Crispr-CPF1-related methods, compositions and components for cancer immunotherapy (2025-06-10),

2. 12286727 - Assessing nuclease cleavage (2025-04-29),

3. 12264331 - Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA (2025-04-01),

4. 12049651 - Cas9 fusion molecules, gene editing systems, and methods of use thereof (2024-07-30),

5. 11911415 - CRISPR/Cas-related methods and compositions for improving transplantation (2024-02-27),

6. 11692205 - Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA (2023-07-04),

7. 11236313 - Cas9 fusion molecules, gene editing systems, and methods of use thereof (2022-02-01),

8. 11180793 - Evaluation of Cas9 molecule/guide RNA molecule complexes (2021-11-23),

9. 11028411 - Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA (2021-06-08),

10. 10494649 - Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA (2019-12-03),

11. 10006054 - Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA (2018-06-26),

12. 9963719 - Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA (2018-05-08),

Title: Inventor Profile: Hariharan Jayaram

Introduction

Hariharan Jayaram is a prominent inventor based in Cambridge, MA, known for his significant contributions to the field of cancer immunotherapy. With an impressive portfolio of 12 patents, he has made strides in genetic engineering that aim to enhance treatment options for patients.

Latest Patents

Among his latest innovations are two notable patents: "CRISPR/Cpf1-related methods, compositions, and components for cancer immunotherapy," which focuses on using CRISPR technology for cancer treatment, and "Assessing nuclease cleavage," detailing systems and methods for analyzing the cleavage profiles of nucleases.

Career Highlights

Hariharan currently operates at Editas Medicine, Inc., a leading organization in the realm of genomic medicine. His research and innovations aim to push the boundaries of how gene editing can be utilized in therapeutic applications, particularly in oncology.

Collaborations

At Editas Medicine, Hariharan collaborates closely with fellow inventor Ari E. Friedland. This teamwork fosters a rich environment of innovation and knowledge exchange, significantly augmenting the research and development process within the company.

Conclusion

In summary, Hariharan Jayaram stands out as a notable inventor in the biotechnology sector, specifically in cancer therapy through his pioneering work with CRISPR technology. His contributions not only reflect his expertise but also hold the potential to transform treatment paradigms in oncology for the future.